Valo is a new type of technology company, uniting human and machine intelligence aiming to accelerate the creation of life-changing cures.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $400M
Founded date: 2018
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 11.03.2021 | Series B | $110M | - |
| 13.01.2021 | Series B | $190M | - |
| 07.10.2020 | - | $100M | - |
Mentions in press and media 27
| Date | Title | Description |
| 03.03.2026 | Diversity will define the next era of biotech infrastructure | - |
| 08.01.2025 | Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases | Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular disease Expanded collaboration includes nea... |
| 25.03.2024 | Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior | Novo Nordisk is adding on to its cardiovascular drug pipeline with the acquisition of Cardior Pharmaceuticals, a genetic medicines developer whose lead program is in mid-stage clinical testing in heart failure. The Danish pharmaceutical gia... |
| 16.02.2023 | Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs | Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets Charles River Laboratories International, announced a multi-program agreement with Pioneering Medicines, a strateg... |
| 10.01.2023 | The billionaire CEO of a top biotech VC firm details how a new type of AI could transform how we test and discover treatments | Flagship Pioneering CEO Noubar Afeyan. Flagship Pioneering Artificial intelligence has the power to revolutionize biotech, Noubar Afeyan says. Afeyan is the CEO and founder of Flagship Pioneering, the venture firm behind Moderna. Flagship h... |
| 10.11.2021 | Valo Health and Khosla Ventures Acquisition Co. Announce Additional PIPE Commitments | BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and develo... |
| 10.06.2021 | Will legislation on competing with China spur the next big thing akin to the internet? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Earlier this week, the U.S. Senate passed bipartisan legislation aimed at boosting the country’s ... |
| 09.06.2021 | Khosla Ventures Acquisition : Valo Health and Khosla Ventures Acquisition Co. to Combine and Create Publicly Traded Company Focused on Transforming the Drug Discovery and Development Process | BOSTON, June 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khos... |
| 09.06.2021 | Khosla Ventures Acquisition : Valo Health and Khosla Ventures Acquisition Co. to Combine and Create Publicly Traded Company Focused on Transforming the Drug Discovery and Development Process (Form 8-K... | Valo Health and Khosla Ventures Acquisition Co. to Combine and Create Publicly Traded Company Focused on Transforming the Drug Discovery and Development Process • Valo is building a fully integrated end-to-end human-centric AI-driven drug d... |
| 11.03.2021 | Valo Health Raises $110M In Series B Funding | Valo Health, a Boston, MA-based technology company focused on improving the drug discovery and development process, received a $110m investment from Koch Disruptive Technologies (KDT). The company also held the final closing of its Series B... |
Show more